Sign In
Buy OKYO
$1.66
-0.0400 (-2.35%)
At Close: Jun 03, 2026
OKYO Pharma chairman acquires more shares in the company
08:35am, Wednesday, 21'st Aug 2024
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has been notified that Panette Partners Limited, an entity in which its chairman Gabriele Cerrone has a beneficial interest, has purchased 35,000 shares
OKYO Pharma Announces Chairman Acquires Shares
07:00am, Wednesday, 21'st Aug 2024
LONDON and NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflam
OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
12:13pm, Thursday, 15'th Aug 2024
LONDON and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflam
OKYO Pharma lands European patent protection for lead asset
08:40am, Tuesday, 06'th Aug 2024
OKYO Pharma Ltd (NASDAQ:OKYO) has been granted a European patent for its lead asset, OK-101. Entitled Compositions Comprising Chemerin Analogs and Methods of Use, it covers OK-101 chemerin analogs, st
OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use
07:00am, Tuesday, 06'th Aug 2024
LONDON and NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflam
OKYO Pharma dry eye disease trial to get underway in the third quarter
08:41am, Thursday, 11'th Jul 2024
OKYO Pharma Ltd (NASDAQ:OKYO) plans to begin a phase II clinical trial for OK-101, targeting neuropathic corneal pain (NCP), in the third quarter. In earlier studies, OK-101 showed significant pain re
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
07:00am, Thursday, 11'th Jul 2024
LONDON and NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflam
OKYO Pharma shares encouraging dry eye data
09:10am, Wednesday, 10'th Jul 2024
OKYO Pharma Ltd (NASDAQ:OKYO) has shared encouraging results from a phase II trial of its treatment candidate for dry eye disease. The study involved 240 patients and showed that 68% of them had imp
OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease
07:00am, Wednesday, 10'th Jul 2024
LONDON and NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflam
LONDON and NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of infla
OKYO Pharma to include additional analyses in upcoming dry eye disease Key Opinion Leader event
08:39am, Tuesday, 09'th Apr 2024
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it is rescheduling its Key Opinion Leader event on the results of its Phase 2 trial of lead asset OK-101 in dry eye disease originally planned for April
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
07:00pm, Monday, 08'th Apr 2024
LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of infla
LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of infla
OKYO Pharma says OK-101 shows statistically significant improvements for dry eye symptoms
08:52am, Friday, 22'nd Mar 2024
OKYO Pharma Ltd (NASDAQ:OKYO) unveiled new results showing its lead drug OK-101 has shown significant and measurable improvements in various indicators and symptoms associated with Dry Eye Disease (DE
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief
